LT3837256T - Karbamido junginiai ir kompozicijos kaip smarca2 / brm atfazės inhibitoriai - Google Patents

Karbamido junginiai ir kompozicijos kaip smarca2 / brm atfazės inhibitoriai

Info

Publication number
LT3837256T
LT3837256T LTEPPCT/IB2019/056847T LTIB2019056847T LT3837256T LT 3837256 T LT3837256 T LT 3837256T LT IB2019056847 T LTIB2019056847 T LT IB2019056847T LT 3837256 T LT3837256 T LT 3837256T
Authority
LT
Lithuania
Prior art keywords
smarca2
compositions
urea compounds
atpase inhibitors
brm atpase
Prior art date
Application number
LTEPPCT/IB2019/056847T
Other languages
English (en)
Lithuanian (lt)
Inventor
Christopher Adair
Julien Papillon
Katsumasa Nakajima
Troy Douglas SMITH
Rukundo Ntaganda
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT3837256T publication Critical patent/LT3837256T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/IB2019/056847T 2018-08-17 2019-08-12 Karbamido junginiai ir kompozicijos kaip smarca2 / brm atfazės inhibitoriai LT3837256T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862765138P 2018-08-17 2018-08-17
PCT/IB2019/056847 WO2020035779A1 (en) 2018-08-17 2019-08-12 Urea compounds and compositions as smarca2/brm atpase inhibitors

Publications (1)

Publication Number Publication Date
LT3837256T true LT3837256T (lt) 2023-06-12

Family

ID=68072895

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/IB2019/056847T LT3837256T (lt) 2018-08-17 2019-08-12 Karbamido junginiai ir kompozicijos kaip smarca2 / brm atfazės inhibitoriai

Country Status (21)

Country Link
US (2) US11958846B2 (cg-RX-API-DMAC7.html)
EP (2) EP4219488A1 (cg-RX-API-DMAC7.html)
JP (1) JP7328323B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210047313A (cg-RX-API-DMAC7.html)
CN (2) CN112585136B (cg-RX-API-DMAC7.html)
AU (1) AU2019322325B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021002632A2 (cg-RX-API-DMAC7.html)
CA (1) CA3107097A1 (cg-RX-API-DMAC7.html)
CY (1) CY1126039T1 (cg-RX-API-DMAC7.html)
DK (1) DK3837256T3 (cg-RX-API-DMAC7.html)
ES (1) ES2946060T3 (cg-RX-API-DMAC7.html)
FI (1) FI3837256T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230477T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061963T2 (cg-RX-API-DMAC7.html)
LT (1) LT3837256T (cg-RX-API-DMAC7.html)
MX (1) MX2021001804A (cg-RX-API-DMAC7.html)
PL (1) PL3837256T3 (cg-RX-API-DMAC7.html)
PT (1) PT3837256T (cg-RX-API-DMAC7.html)
RS (1) RS64238B1 (cg-RX-API-DMAC7.html)
SI (1) SI3837256T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020035779A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
EP3746124A4 (en) 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
CN112585136B (zh) 2018-08-17 2024-06-25 诺华股份有限公司 作为smarca2/brm atp酶抑制剂的脲化合物和组合物
US12473334B2 (en) 2018-10-17 2025-11-18 Dana-Farber Cancer Institute, Inc. SWI/SNF family chromatin remodeling complexes and uses thereof
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155264A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155262A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
CN112979646B (zh) * 2021-03-08 2022-01-14 北京富龙康泰生物技术有限公司 一种咪唑并吡啶类衍生物
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
EP4734993A2 (en) * 2023-06-30 2026-05-06 Dana-Farber Cancer Institute, Inc. Methods for sensitizing drug-resistant cancer cells

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US2871243A (en) * 1956-10-26 1959-01-27 May & Baker Ltd 5-amino-3-methyl-isothiazole and process
AUPP003197A0 (en) 1997-09-03 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Mek阻害剤による関節炎の治療
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US7304066B2 (en) 2001-05-24 2007-12-04 Bjoerkling Fredrik Pyridyl cyanoguanidine compounds
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2478065C (en) 2002-03-08 2013-01-08 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
JP2006521345A (ja) 2003-03-28 2006-09-21 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ニコチン性アセチルコリン受容体の正のアロステリック調節剤
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US8455513B2 (en) * 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
CN103463084A (zh) 2008-03-14 2013-12-25 大塚制药株式会社 制剂组合物在制备治疗以mmp-2及/或mmp-9为起因的肺气肿的药物中的应用
CN103880737A (zh) * 2014-02-27 2014-06-25 浙江泰达作物科技有限公司 1-(2-氯-4-吡啶基)-3-苯基脲的制备方法
DK3169671T3 (da) 2014-07-17 2019-09-23 Sunshine Lake Pharma Co Ltd 1-(5-(tert.-butyl)isoxazol-3-yl)-3-(4-((phenyl)ethynyl)phenyl)ureaderivater og relaterede forbindelser som flt3-inhibitorer til behandling af kræft
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
CN105481723B (zh) 2015-04-29 2017-08-25 中国农业大学 一种非均相催化的烷基/苄基/芳基脲类化合物的制备方法
WO2018187414A1 (en) 2017-04-05 2018-10-11 The Regents Of The University Of California Inhibitors of mtor-rictor interactions
CN112585136B (zh) * 2018-08-17 2024-06-25 诺华股份有限公司 作为smarca2/brm atp酶抑制剂的脲化合物和组合物
WO2020126968A2 (en) 2018-12-20 2020-06-25 Bayer Aktiengesellschaft Urea derivatives

Also Published As

Publication number Publication date
US20240270738A1 (en) 2024-08-15
PL3837256T3 (pl) 2023-07-10
FI3837256T3 (fi) 2023-05-15
CN118666832A (zh) 2024-09-20
JP7328323B2 (ja) 2023-08-16
US20210323956A1 (en) 2021-10-21
AU2019322325B2 (en) 2022-01-20
EP3837256A1 (en) 2021-06-23
JP2021534147A (ja) 2021-12-09
HRP20230477T1 (hr) 2023-07-21
RS64238B1 (sr) 2023-06-30
SI3837256T1 (sl) 2023-07-31
AU2019322325A1 (en) 2021-02-18
CN112585136A (zh) 2021-03-30
CN112585136B (zh) 2024-06-25
EP4219488A1 (en) 2023-08-02
DK3837256T3 (da) 2023-05-30
ES2946060T3 (es) 2023-07-12
HUE061963T2 (hu) 2023-09-28
WO2020035779A1 (en) 2020-02-20
BR112021002632A2 (pt) 2021-05-11
US11958846B2 (en) 2024-04-16
KR20210047313A (ko) 2021-04-29
PT3837256T (pt) 2023-05-23
EP3837256B1 (en) 2023-03-08
CA3107097A1 (en) 2020-02-20
CY1126039T1 (el) 2023-11-15
MX2021001804A (es) 2021-04-19
US12358906B2 (en) 2025-07-15

Similar Documents

Publication Publication Date Title
DK3837256T3 (da) Ureaforbindelser og sammensætninger som smarca2/brm-atpase-hæmmere
DK3442973T3 (da) Hidtil ukendte forbindelser som autotaxinhæmmere og farmaceutiske sammensætninger omfattende samme
EP3891284A4 (en) Oligonucleotide compositions and methods thereof
EP3823673A4 (en) ANTI-CD112R COMPOSITIONS AND METHODS
EP3694530A4 (en) COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
EP3664815A4 (en) OLIGONUCLEOTIDE COMPOSITIONS AND METHOD FOR THEREFORE
LT3607069T (lt) Produktai ir kompozicijos
EP3917527C0 (en) COMPOUNDS AND THEIR USES
LT3510033T (lt) Junginiai ir kompozicijos kaip endosominių toll tipo receptorių inhibitoriai
EP3352774A4 (en) FLAVONOID COMPOSITIONS AND METHODS OF USE
EP3625229A4 (en) SOLID FORMS OF BERBERINE SODEOXYCHOLATE AND COMPOSITIONS AND METHODS FOR THEREFORE
EP3833343A4 (en) HETEROCYCLIC FLAVON DERIVATIVES, COMPOSITIONS AND RELATED METHODS THEREOF
EP3368541A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
EP3565397A4 (en) MICROBIAL COMPOSITIONS AND METHODS
EP3599868C0 (en) HERBICIDE MIXTURE, COMPOSITION AND PROCESS
EP3688011A4 (en) PEPTIDE COMPOSITIONS AND METHOD FOR THEIR USE
EP3826638A4 (en) ELAGOLIX SODIUM COMPOSITIONS AND RELATED METHODS
EP3924341A4 (en) Compounds, compositions and methods
SI3442947T1 (sl) Z aminom substituirane arilne ali heteroarilne spojine kot inhibitorji ehmt1 in ehmt2
DK3255042T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme
DK3494119T3 (da) Forbindelser og sammensætninger og anvendelser deraf
EP3606465A4 (en) Dosing regimens and related compositions and methods
EP3503733C0 (en) INSECT-REPELLENT COMPOUNDS AND COMPOSITIONS AND ASSOCIATED METHODS
MA51162A (fr) Schémas posologiques et compositions et procédés associés
EP3625234A4 (en) COMPOUNDS, COMPOSITIONS AND PROCEDURES